Add this topic to your myFT Digest for news straight to your inbox
Group of 11 pharma, tech and luxury shares echoes US dominance of ‘Magnificent Seven’
Companies analysis from our sister publication
Strong uptake of UK pharma group’s vaccine has helped to ease fears of a patent cliff
Forerunners of pharma company tested vaccines at notorious institutions for decades
Shots will be given to children in Cameroon as part of rollout of up to 30mn jabs across continent
UK pharma group hopes acquisition of three-month start-up will broaden its range of asthma treatments
UK pharma group says country’s chemistry prowess makes it a good source of molecules
First jab for respiratory syncytial virus powers sales at UK drugmaker
UK drugmaker reaches agreement in US over cases tied to allegations heartburn medicine causes cancer
Agreement is first of its kind in China for UK-based pharma group
Accenture legal team wins FT award for its work on taking risks with confidence
Scientists hail ‘entirely novel approach’ to controlling a disease that kills more than 600,000 a year
Drugmaker does not specify reason but forex shortage has put pressure on multinationals
Drugmaker projects rise in revenue of up to 10% after consensus-beating second quarter
Deal avoids California trial over allegations that group’s medication caused cancer
Former GSK and Pfizer joint venture shines
Industry watchers say UK-listed rival AstraZeneca has a stronger pipeline and benefits from its oncology expertise
US regulators say drugmaker’s Xevudy fails to tackle most prevalent variants of coronavirus
Modest size of acquisition leaves the UK pharma group well positioned to make further bolt-on deals
UK pharma group agrees to buy Bellus Health in effort to strengthen pipeline
UK drugmaker’s shingles vaccine boosts sales while demand for Covid-related products falls
Sebastien de La Riviere’s move is latest in a number of high-profile departures inside activist’s London office
A greater focus on innovation should top the UK pharma chief executive’s agenda
Chief commercial officer Luke Miels looking at targets worth up to $2.5bn
UK Edition
